Russian biopharmaceutical company BIOCAD is the first company in the country to launch a 150-million-dollar effort to supply therapeutic products based on monoclonal antibodies to several countries outside Russia. In the end of December BIOCAD made its first shipment to Vietnam. The country received high-tech product for treatment of certain types of blood cancer. This was the first shipment under the 5-year contract with a local distributor. Previously, the Vietnamese patients could count only on the original products by Swiss global healthcare company F. Hoffmann-La Roche, but at a much higher price.
“Success of Russia’s biosimilar rituximab has several ingredients. The product’s high quality was proven in sizeable multinational clinical trials, yet its price is much lower than the originator’s. This opened new opportunities to supply biosimilar rituximab to the patients who knew that the original product had been prohibitively expensive for them.” says BIOCAD’s founder and CEO, Mr. Dmitri Morozov.
By now, BIOCAD has already signed more than a dozen agreements with the distribution and manufacturing companies in several countries of South-East Asia, such as the Philippines, Malaysia, Indonesia, and Thailand. Advanced Russian biotech products that are used for therapy of oncological and autoimmune diseases are in high demand WW. They are no inferior to the original products made by the leading Western companies, yet cost significantly less.